Alvogen and Reddy’s Cleared Over US Rivals To Suboxone
Alvogen and Dr Reddy’s do not infringe key patents protecting Indivior’s Suboxone Film, the US Court of Appeals has confirmed. But Teva continues to fall foul of a production patent running until 2024.
You may also be interested in...
Dr Reddy’s is in line for a $72m payout after settling US patent and antitrust litigation over Suboxone with Indivior.
Indivior has agreed to pay $10m to settle antitrust charges by the US Federal Trade Commission over its Suboxone brand.
With Erez Israeli set to step up from COO to CEO, Dr Reddy’s is looking to leverage its lack of debt and strong cash flow in the mergers and acquisitions arena.